Theriault RL - Search Results

1

The role of serum CEA as a prognostic indicator in stage II and III breast cancer patients treated with adjuvant chemotherapy.

Theriault RL, Hortobagyi GN, Fritsche HA, Frye D, Martinez R, Buzdar AU. Theriault RL, et al. Cancer. 1989 Mar 1;63(5):828-35. doi: 10.1002/1097-0142(19890301)63:5<828::aid-cncr2820630506>3.0.co;2-3. Cancer. 1989. PMID: 2914290

2

Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.

Dhingra K, Frye D, Newman RA, Walters R, Theriault R, Fraschini G, Smith T, Buzdar A, Hortobagyi GN. Dhingra K, et al. Clin Cancer Res. 1995 Jul;1(7):691-7. Clin Cancer Res. 1995. PMID: 9816034 Clinical Trial.

3

Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer.

Holmes FA, Walters RS, Theriault RL, Forman AD, Newton LK, Raber MN, Buzdar AU, Frye DK, Hortobagyi GN. Holmes FA, et al. Among authors: theriault rl. J Natl Cancer Inst. 1991 Dec 18;83(24):1797-805. doi: 10.1093/jnci/83.24.1797-a. J Natl Cancer Inst. 1991. PMID: 1683908 Clinical Trial.

4

Clinical course of patients with breast cancer with ten or more positive nodes who were treated with doxorubicin-containing adjuvant therapy.

Buzdar AU, Kau SW, Hortobagyi GN, Ames FC, Holmes FA, Fraschini G, Hug V, Theriault RL, McNeese MD, Singletary SE. Buzdar AU, et al. Among authors: theriault rl. Cancer. 1992 Jan 15;69(2):448-52. doi: 10.1002/1097-0142(19920115)69:2<448::aid-cncr2820690229>3.0.co;2-k. Cancer. 1992. PMID: 1728373

5

Inflammatory carcinoma of the breast: results of a combined-modality approach--M.D. Anderson Cancer Center experience.

Koh EH, Buzdar AU, Ames FC, Singletary SE, McNeese MD, Frye D, Holmes FA, Fraschini G, Hug V, Theriault RL, et al. Koh EH, et al. Among authors: theriault rl. Cancer Chemother Pharmacol. 1990;27(2):94-100. doi: 10.1007/BF00689090. Cancer Chemother Pharmacol. 1990. PMID: 2249339

6

Pirarubicin in combination chemotherapy for metastatic breast cancer.

Hortobagyi GN, Theriault RL, Frye D, Walters RS, Fraschini G, Tashima CK, Ro JS, Salewski E, Buzdar AU. Hortobagyi GN, et al. Among authors: theriault rl. Am J Clin Oncol. 1990;13 Suppl 1:S54-6. doi: 10.1097/00000421-199012001-00012. Am J Clin Oncol. 1990. PMID: 2291460

7

Sequential multiagent chemotherapy incorporating cisplatin, doxorubicin, and cyclophosphamide in the treatment of metastatic breast cancer.

Theriault RL, Hortobagyi GN, Kau SW, Holmes FA, Hug V, Fraschini G, Jabboury K, Buzdar AU. Theriault RL, et al. Cancer. 1988 Nov 15;62(10):2105-10. doi: 10.1002/1097-0142(19881115)62:10<2105::aid-cncr2820621006>3.0.co;2-n. Cancer. 1988. PMID: 3179923

8

The M. D. Anderson Cancer Center experience with Taxol in metastatic breast cancer.

Holmes FA, Valero V, Walters RS, Theriault RL, Booser DJ, Fraschini G, Buzdar AU, Frye D, Gibbs HR, Hortobagyi GN. Holmes FA, et al. Among authors: theriault rl. J Natl Cancer Inst Monogr. 1993;(15):161-9. J Natl Cancer Inst Monogr. 1993. PMID: 7912522 Clinical Trial.

9

Use of Taxol (paclitaxel) in breast cancer.

Hortobagyi GN, Holmes FA, Theriault RL, Buzdar AU. Hortobagyi GN, et al. Among authors: theriault rl. Oncology. 1994 Oct;51 Suppl 1:29-32. doi: 10.1159/000227413. Oncology. 1994. PMID: 7970507

10

Phase I trial of droloxifene in patients with metastatic breast cancer.

Buzdar AU, Kau S, Hortobagyi GN, Theriault RL, Booser D, Holmes FA, Walters R, Krakoff IH. Buzdar AU, et al. Among authors: theriault rl. Cancer Chemother Pharmacol. 1994;33(4):313-6. doi: 10.1007/BF00685906. Cancer Chemother Pharmacol. 1994. PMID: 8281625 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

214 results

Search Page

Filters